Novartis’ generics unit Sandoz will tell investors today that it can add $3 billion in annual sales from the launch of new products, after it spins out of its parent compa
Digital health company Akili has launched a non-prescription version of its attention-deficit hyperactivity disorder (ADHD) digital therapeutic EndeavorRx, that can be dow
Danish pharma group Novo Nordisk has revealed it is in exclusive negotiations that could result in the acquisition of a controlling stake in Biocorp, a French company that
Novartis’ IL-17 inhibitor Cosentyx has become the first new biological therapy for the painful skin condition hidradenitis suppurativa (HS) in nearly a decade, following i
Billionaire and celebrity entrepreneur Mark Cuban has revealed his latest move to tackle the cost of medicines in the US, agreeing a deal to make a low-cost biosimilar ver